Use of peptidic bradykinin antagonists for the treatment and prevention of Alzheimer's disease

US6245736A · kind A · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Holger Heitsch · Hofheim, DE
• Stephan Henke · Bad Soden am Taunus, DE
• Gerhard Breipohl · Scheinfeld, DE
• Jochen Knolle · Kriftel, DE
• Klaus Wirth · Frankfurt am Main, DE
• Gabriele Wiemer · Kronberg, DE

Key dates

• Filing date: Oct 14, 1997
• Grant date: Jun 12, 2001
• Expiry date: Oct 14, 2017

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K7/18
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the use of bradykinin antagonists for the production of pharmaceuticals for the treatment and prevention of Alzheimer's disease. Suitable bradykinin antagonists are peptides which inhibit the effects of the Alzheimer's protein amyloid (.beta./A4) on isolated endothelial cells. A particularly suitable peptide is H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH (HOE 140) and its physiologically tolerable salts.